A Phase 3 interventional study of Nefecon 16mg daily in Primary IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Completed at 18 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Calliditas Therapeutics AB · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 24th largest by enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 in phase 3, and was the 26th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 22 · Phase 4 7
First in 1997; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 67 across the 67 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 73 have an industry lead sponsor. The 10 most frequent:
Calliditas Therapeutics AB is the lead sponsor of 11 studies on the registry; none are open to participants now.
Calliditas Therapeutics AB has 5 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon. During Study Nef-301 OLE, the patients and Investigators will remain blinded to treatment given in Study Nef-301.
During Study Nef-301 OLE, patients will receive Nefecon for a 9-month period. The dose may be reduced if clinically relevant adverse events (AEs) develop during the 9-month Treatment Period that the Investigator considers related to the study drug and that mandate dose reduction.
Patients will remain on a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) throughout the study. The patient will come for a follow-up visit at 12 months after first dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nefecon 16 mg once daily by mouth for 9 months
Drug: Nefecon 16mg daily
All study patients received Nefecon 16 mg daily for 9 months.
Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline
The outcome is measured as UPCR based on 24 hour urine collections at 9 months following the first dose of Nefecon compared to baseline Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram
Time frame: 9 months
Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline
The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 9 months following the first dose of Nefecon compared to baseline. I.e. eGFR at 9 months divided by eGFR at Baseline.
Time frame: 9 months
Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline
Ratio of urine albumin to creatinine ratio (UACR) measured by 24h urine sampling at 9 months compared to baseline. I.e. UACR at 9 months divided by eGFR at Baseline.
Time frame: 9 months
Change From Baseline Short Form 36 (SF-36) Quality of Life Assessment at 12 Months
Short Form 36 (SF-36) quality of life assessment at 12 months compared to baseline, i.e. change from baseline. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved, i.e. 0 is the minimum and 100 is the maximum score.
Time frame: Baseline & 12 months
Number of Patients With Microhematuria at 9 Months Compared to Baseline
Time frame: 9 months
Number of Patients Receiving Rescue Treatment
Systemic immunosuppressive drugs (including glucocorticoids in some situations ), dialysis, and renal transplantation are considered as rescue medications in this study.
Time frame: 12 months
Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2
Looking at number of patients with end stage kidney disease defined as being on dialysis, undergoing kidney transplantation, or having eGFR \<15 mL/min per 1.73 m2
Time frame: 12 months
Change From Baseline Cortisol Suppression at 9 Months
Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.
Time frame: Baseline & 9 months
Change From Baseline Cortisol Suppression at 12 Months
Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.
Time frame: Baseline & 12 months
| Milestone | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Started | 45 | 74 |
| Completed | 43 | 62 |
| Not completed | 2 | 12 |
The outcome is measured as UPCR based on 24 hour urine collections at 9 months following the first dose of Nefecon compared to baseline Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram
| ratio | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline | 0.67 (0.56 to 0.80) | 0.69 (0.60 to 0.80) |
The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 9 months following the first dose of Nefecon compared to baseline. I.e. eGFR at 9 months divided by eGFR at Baseline.
| ratio | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline | 0.97 (0.94 to 1.01) | 0.97 (0.94 to 1.00) |
Ratio of urine albumin to creatinine ratio (UACR) measured by 24h urine sampling at 9 months compared to baseline. I.e. UACR at 9 months divided by eGFR at Baseline.
| ratio | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline | 0.60 (0.49 to 0.75) | 0.65 (0.55 to 0.77) |
Short Form 36 (SF-36) quality of life assessment at 12 months compared to baseline, i.e. change from baseline. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved, i.e. 0 is the minimum and 100 is the maximum score.
| Change in percentage of total Score | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Bodily Pain | -4.518 ± 10.0522 | -3.756 ± 9.9213 |
| General Health | -4.290 ± 7.4076 | -3.301 ± 5.8211 |
| Mental Component Summary | -2.282 ± 7.1270 | -1.061 ± 6.6251 |
| Mental Health | -1.725 ± 7.1576 | -1.570 ± 6.3522 |
| Physical Component Summary | -3.952 ± 6.6367 | -3.403 ± 6.1115 |
| Physical Functioning | -2.697 ± 7.4670 | -1.996 ± 6.6726 |
| Role Emotional | -2.928 ± 7.2390 | -0.747 ± 7.4962 |
| Role Physical | -3.421 ± 7.1914 | -2.793 ± 7.6901 |
| Social Function | -4.102 ± 8.4631 | -2.364 ± 6.3713 |
| Vitality | -2.633 ± 7.6406 | -2.376 ± 7.6968 |
| Participants | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Number of Patients With Microhematuria at 9 Months Compared to Baseline | 10 | 17 |
Systemic immunosuppressive drugs (including glucocorticoids in some situations ), dialysis, and renal transplantation are considered as rescue medications in this study.
| Participants | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Number of Patients Receiving Rescue Treatment | 1 | 0 |
Looking at number of patients with end stage kidney disease defined as being on dialysis, undergoing kidney transplantation, or having eGFR \<15 mL/min per 1.73 m2
| Participants | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2 | 2 | 0 |
Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.
| ug/day) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Change From Baseline Cortisol Suppression at 9 Months | -24.122 ± 25.1690 | -32.126 ± 30.6978 |
Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.
| ug/day | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Change From Baseline Cortisol Suppression at 12 Months | -7.660 ± 27.4262 | -11.954 ± 25.8052 |
Collected over All-Cause Mortality, SAEs and non-serious AEs were assessed from date of first dose of study treatment until 12 months after the first dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Retreatment - Previously Treated With Nefecon in Nef-301 Study | 0/45 (0%) | 5/45 (11.1%) | 32/45 (71.1%) |
| Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | 0/74 (0%) | 5/74 (6.8%) | 46/74 (62.2%) |
| Event | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| LymphadenopathyBlood and lymphatic system disorders | 1/45 | 0/74 |
| Joint dislocationInjury, poisoning and procedural complications | 1/45 | 0/74 |
| Central nervous system vasculitisNervous system disorders | 1/45 | 0/74 |
| Atrial fibrillationCardiac disorders | 1/45 | 0/74 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/45 | 0/74 |
| HaematuriaRenal and urinary disorders | 1/45 | 0/74 |
| Monoclonal B-cell lymphocytosisBlood and lymphatic system disorders | 0/45 | 1/74 |
| Scapula fractureInjury, poisoning and procedural complications | 0/45 | 1/74 |
| HeadacheNervous system disorders | 0/45 | 1/74 |
| ChorioretinopathyEye disorders | 0/45 | 1/74 |
| Event | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study |
|---|---|---|
| Corona virus infectionInfections and infestations | 12/45 | 13/74 |
| HypertensionVascular disorders | 8/45 | 12/74 |
| Oedema peripheralGeneral disorders | 1/45 | 10/74 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/45 | 5/74 |
| Weight increasedInvestigations | 3/45 | 8/74 |
| FatigueGeneral disorders | 4/45 | 2/74 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/45 | 3/74 |
| HeadacheNervous system disorders | 4/45 | 3/74 |
| ProteinuriaRenal and urinary disorders | 4/45 | 5/74 |
| AcneSkin and subcutaneous tissue disorders | 3/45 | 6/74 |
| Age, Continuous(years) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| Median | 46 (29 to 70) | 47 (25 to 76) | 47 (25 to 76) |
| Sex: Female, Male(Participants) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| Female | 6 | 19 | 25 |
| Male | 39 | 55 | 94 |
| Race (NIH/OMB)(Participants) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 7 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 36 | 64 | 100 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Region of Enrollment(participants) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| Argentina | 6 | 3 | 9 |
| Czechia | 2 | 13 | 15 |
| United States | 6 | 5 | 11 |
| United Kingdom | 3 | 3 | 6 |
| Belarus | 1 | 1 | 2 |
| Spain | 1 | 1 | 2 |
| Greece | 3 | 5 | 8 |
| Canada | 7 | 7 | 14 |
| South Korea | 2 | 4 | 6 |
| Sweden | 1 | 2 | 3 |
| Turkey | 0 | 2 | 2 |
| Belgium | 4 | 3 | 7 |
| Finland | 1 | 3 | 4 |
| Poland | 0 | 3 | 3 |
| Italy | 2 | 1 | 3 |
| Australia | 2 | 7 | 9 |
| France | 1 | 3 | 4 |
| Germany | 3 | 8 | 11 |
| Urine Protein to Creatine Ratio (UPCR)(g/gram) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| Geometric mean | 1.253 (0.859 to 1.796) | 1.339 (1.000 to 1.881) | 1.306 (0.935 to 1.881) |
| Baseline Estimated glomerular filtration rate (eGFR)(ml/min/1.73 m2) | Retreatment - Previously Treated With Nefecon in Nef-301 Study | Delayed Treatment - Previously Treated With Placebo in Nef-301 Study | Total |
|---|---|---|---|
| Geometric mean | 51.0 (42.0 to 62.0) | 49.9 (39.9 to 64.9) | 50.3 (39.9 to 63.5) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Feb 2024, 39 months.
Results were first posted in Jan 2025, 10 months after primary completion.
Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 39 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Calliditas Therapeutics AB